Resitu: minimally invasive surgical technology

News and press releases

Follow Resitu's path towards creating a paradigm shift in the management of breast cancer. Read up on news, press releases and clinical studies.

Popular workshop at the Uppsala Breast Meeting

There was a great interest in the Resitu technology in the workshop we hosted at the Uppsala Breast Meeting. We had to divide participants into several groups to make room for everyone who wanted to see or try the instrument. Thanks to all of you who were there!

Resitu medical interview in newspaper Dagens Industri

Resitu Medical article in Dagens Industri

You can now read about how Resitu Medical aims to make Breast Cancer Care more efficient in Dagens Industri. Our CCO, Therese Sundell, has been interviewed to explain how the Resitu technology could be used to achieve this goal.

Resitu at the ESSO congress in Florence

This week we are in beautiful Florence at the ESSO congress. If you are here too, come visit us in booth #1!

SVD article with Resitu CCO Therese Sundell

Today breast cancer treatment is a stressful, multi-step process with long waiting times. Read the article in Svenska Dagbladet about how Resitu will shorten the process and revolutionize breast cancer management.

Pink Ribbon 20 Years

We are pleased to sponsor the Pink Ribbon Campain this year again. It is great to be able to contribute to important cancer reasearch and bring attention to breast cancer.

Resitu Medical at Almi Invest Digital Demo Day

Our CCO Therese Sundell participated in a digital Life Science pitch event arranged by Almi Invest, offering the opportunity to invest in Resitu Medical. The event is available to take part of starting at 25 minutes.

Resitu Pitching at Life Science Event

Our CCO Therese Sundell has been in Malmö at the Life Science pitch event arranged by Almi Invest Skåne to present an opportunity to invest in Resitu Medical and help us reach FDA clearance and CE mark.

Read about the Resitu Technology in Dagens Nyheter

Andreas Karakatsanis, Breast Surgeon at Akademiska sjukhuset, has been interviewed by DN, regarding the development of the Resitu instrument. A minimally invasive method with potential to revolutionize breast cancer care.

Stefan Sowa awarded CEO of the year

Stefan Sowa has been awarded twice by Business Worldwide Magazine: as "Healthcare CEO of the Year - Sweden" and "Most Innovative CEO in the Medical Device Industry - Europe."

Resitu Technology article in Business Worldwide Media

Today BWM presents the Resitu Technology: Removing breast tissue before it becomes cancerous is often a race against time. Resitu’s cutting edge medical device has the potential to enable diagnosis and treatment in one step.

Great interest in the Resitu technology at Lab & Diagnostics meeting

At the conference Lab & Diagnostics for the Future we demonstrated the Resitu Technology to many interested conference visitors by taking samples from a water melon.

Resitu Medical receives grant from SWElife and MedTech4Health

Resitu Medical receives a 3 MSEK grant from SWElife and MedTech4Health for "development of an innovative instrument for biopsy and treatment of changes in breast tissue"

Meet us at Lab & Diagnostics of The Future

Resitu Medical will participate at this partnering event on April 12 at Life City in Stockholm, where the aim is to promote collaborations and to highlight tomorrow's innovative lab techniques in different types of diagnostics. 

ISO certification achieved

Resitu Medical has been certified according to ISO 13485, with the following scope: Design, development, manufacturing and sales of electrosurgical instruments for tissue removal, by DQS Medizinprodukte GmbH. This is a major milestone for the company and now we continue working towards submission of the technical file of our first product.

Resitu presenting at UBP Invest 2023

Stefan Sowa, CEO of Resitu Medical will present at UBP Invest 2023 at Uppsala Business Park on February 9:th. If you have a chance to join us, secure your seat and read more about the event here:

Resitu Medical at UBP Community Breakfast

Resitu Medical will talk about the future in breast cancer treatment and show our instrument in development for minimally invasive tissue removal at UBP Community Breakfast Thursday January 26:th at Uppsala Business Park.

Seed round #3 initiated

A seed round of 2 MEUR for introduction of the first product into the EU market has been initiated. The instrument is now in serial production and clinical validation has started. Major shareholders: Novoaim, ALMI Invest, STOAF.

Sampling in avocado in booth A4 at EBCC

Thanks to everyone who has visited our stand at EBCC. It is soon time to leave Barcelona - but before you do we still have a few avocados left if you have not yet tried the Resitu technology.

At the European Breast Cancer Conference

Discussions in booth A4 at EBCC. Come pay us a visit if you are at the congress.

Resitu Medical at EBCC in Barcelona

Resitu Medical will be in Barcelona at the European Breast Cancer Conference, November 16-18 to present our unique Resitu Technology of minimally invasive lesion removal. If you are in Barcelona, visit us in Booth A4 to learn more!

New seed round closed

Resitu Medical has closed the second seed round of 1.5 MEUR mainly by existing shareholders. Major shareholders are Novoaim 60%, ALMI Invest 15% and Stockholm Business Angels (STOAF) 15%.

The development of the first instrument is proceeding according to plan. The product design is finalized and is currently being transferred to production. “The funding will be used to verification, validation, clinical studies, and prepare the documentation for CE mark and FDA submission” says CEO Stefan Sowa.

Resitu Medical announces new visual identity and website

Resitu Medical is happy to release our new website, presenting our new visual identity. The new identity illustrates our vision: Beyond Conventional surgery and our Mission: We design for a minimal invasive surgical technology. Our new visual identity harmonizes with the user friendliness and intuitive ease of use of our products in development and that our products are designed with the user and the patient in focus. The identity and communication aim to reflect our product message Precision made easy. 

Welcome to look around!

Medlim bootcamp

Resitu Medical has been selected as 1 of 16 companies from 68 applicants for the MedLim Matchmaking & Fast Track Acceleration Program. The program is offered to promising startups that develop breakthrough, innovative MedTech products and services in the Cardiovascular, Neurological, Spine & Medical Surgical domains.

EIT health MedTech Accelerator Bootcamp

Resitu Medical was selected for the EIT Health MedTech Accelerator Bootcamp, a six-week online program for promising start-up companies in the medical technology field arranged by EIT Health in collaboration with UnterNehmerThum, IESE Business school and FAU university. The team completed the training guided by mentors and experts covering many aspects of starting and building a business in this challenging field, including medical device regulations, market access, financing, market and competitor analysis, business case and pitch presentation, and the importance of having the right team.

Resitu Medical wins Healthy Longevity Catalyst Award and receives 50 kUSD

Resitu Medical  is one of 154 winners selected among 1500 applicants from 50 countries to win the Healthy Longevity Catalyst Award from the US National Academy of Medicine,  and receives 50 kUSD. Resitu Medical was selected by EIT Health as 1 of 21 winners  from more than 400 applicants in the European Union.

We would like thank the National Academy of Medicine and EIT Health for selecting Resitu Medical as a winner of the Healthy Longevity Catalyst Award. We aim to contribute to health and longevity by enabling correct and early diagnosis and faster treatment of breast cancer. The true winners will be the women with breast lesions and tumours who will get access to the minimally invasive Resitu technology offering them a fast and safe diagnosis giving better treatment outcomes. Our cost effective technology will also bring substantial health economic gains for the benefit of the society. 

Resitu Medical welcomes Henrik

We are happy to announce that we have recruited Henrik Thunqvist as a new employee. Henrik has collaborated with Resitu Medical when writing his master thesis, to finish his studies of Engineering Physics in Uppsala. 

Almi Invest and STOAF invest in Resitu's new treatment of breast cancer

Almi Invest and STOAF III Scitech invest 2.5 MSEK each in Resitu Medical, for their development of a new instrument for early treatment of breast cancer. Other private investors are also participating in the issue totalling SEK 7.5 million. The money will be used for product development of a version of the instrument ready for CE marking.

€750 000 to EIT Health company Resitu Medical

The medical technology company Resitu Medical AB, working with an innovative solution for tumor biopsies, announced today that Almi Invest, Stockholm Business Angels (STOAF) and private investors have invested €750 000 in the company. The investment will be used to initiate a development project aiming for CE marking in 2023. An additional SEK 20 million will be raised through equity.

Nordic Life Science News

Resitu Medical has received a 50,000 Euro grant from the EIT Health Headstart programme. 

Scandinavian startups receiving in total up to €700,000 in funding

Resitu Medical is one of the Scandinavian startups selected for the 2020 annual EIT Health Headstart programme.

89 startups from across Europe of which 14 are based in Scandinavia are selected for support to accelerate the development of promising health solutions